Bacteriostatic Antibiotics Market - Size, Share,
Outlook, and Opportunity Analysis, 2018 – 2026
Antibiotics are naturally occurring or artificially produced substances, which are widely used in
the treatment of bacterial diseases. Antibiotics works by killing bacteria (bactericidal effect) or
by inhibiting their growth (bacteriostatic effect). Although bacteriostatic antibiotics prevent
bacterial growth and reproduction, it does not necessarily kill them.
Request Sample Copy of Research Report @
https://www.coherentmarketinsights.com/insight/request-sample/2307
Bacteriostatic Antibiotics Market Drivers
Global bacteriostatic antibiotics market is expected to witness a significant growth over the
forecast period, owing to recent approval and launch of novel bacteriostatic antibiotics products
in the market.
For instance, in September 2018, Tetraphase Pharmaceuticals, Inc., a biopharmaceutical
company dedicated to development, manufacturing, and commercialization of novel antibiotics
for treat life-threatening multidrug-resistant (MDR) infections received European Commission
(EC) marketing authorization for its novel bacteriostatic antibiotic namely XERAVA
(eravacycline) injection, which is indicated for the treatment of complicated intra-abdominal
infections (cIAI) in adults in the European Union. XERAVA (Eravacycline) is a fluorocycline
antibacterial within the tetracycline class of antibacterial drugs, it is bacteriostatic against gram-
positive bacteria (e.g., Staphylococcus aureus and Enterococcus faecalis)
Furthermore, high prevalence of bacterial and infectious disease is expected to propel demand
for bacteriostatic antibiotics, in turn driving global bacteriostatic antibiotics market growth.
For instance, according to the data published by Centers of Disease Control and Prevention
(CDC), in 2016, an estimated 9,272 people suffered from tuberculosis, 53,850 from salmonella,
and 36,429 from Lyme disease in the U.S.